as 1413

Amonafide (NSC-308847,AS1413)(AS1413) produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage.

Amonafide L-malate is the malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.

AT-1413 is a humanized monoclonal antibody (mAb) targeting CD43. It triggers antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. Additionally, AT-1413 shows antitumor activity in an AML mouse model. This compound is applicable for studies involving acute myeloid leukemia, breast cancer, malignant melanoma, and myelodysplastic syndrome. The recommended isotype control is HumanIgG1kappa, Isotype Control.